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Abstract 
Background: In the context of recent guidelines on invasive candidiasis (IC), how French intensive care units (ICUs) 
are managing IC?
Methods: This is a prospective observational multicenter cohort study. During 1 year (2012–2013), 87 French ICUs 
enrolled consecutive patients with suspected or proven IC (SIC or PIC) and receiving systemic antifungal therapy 
(SAT). Data were collected up to 28 days after inclusion.
Results: We studied 835 patients, 291 with PIC and 544 with SIC. At SAT initiation, patients with SIC were significantly 
more severe (SAPS II 50.1 ± 18.7 vs. 46.2 ± 18.0). Severe sepsis or septic shock prompted to initiate empiric SAT in 70 % of 
SIC. Within 4 days in median, the initial SAT was modified in 49 % of patients with PIC vs. 33 % patients with SIC. Modifica‑
tions were most often motivated by mycological results, and de‑escalation was the most frequent change. Regarding 
compliance to IC management guidelines, echinocandin was used for 182 (62.5 %) patients with PIC, and 287 (52.7 %) of 
those with SIC; central venous catheter was removed in 87 (54.3 %) of patients with candidaemia, and 43 of the remain‑
ing patients received echinocandin; and de‑escalation was undertaken after 5 days of SAT in 142 patients, after 10 days 
in 13 patients. As 20.6 % of SIC were secondarily documented, 403/835 (48 %) patients had finally a proven IC. Candida 
albicans was the main pathogen (65.3 %), then Candida glabrata (15.9 %). The 28‑day mortality rates were 40.0 % in can‑
didaemia, 25.4 % in cIAI, and 26.7 % in deep‑seated candidiasis. In the overall population of patients with proven IC, four 
independent prognostic factors were identified: immunosuppression (Odds Ratio (OR) = 1.977: 1.03–3.794 95 % confi‑
dence interval (CI), p = 0.04), age (OR = 1.035; 1.017–1.053 95 % CI; p < 0.001), SAPS >46 on ICU admission (OR = 2.894; 
1.81–4.626 95 % CI; p < 0.001), and surgery just before or during ICU stay (OR = 0.473; 0.29–0.77 95 % CI; p < 0.001).
Conclusion: When SAT is initiated in French ICUs, the IC is ultimately proven for 48 % of patients. Empiric SAT is 
initiated in severely ill ICU patients. The initial SAT is often adapted, with de‑escalation to fluconazole when possible. 
Mortality rate remains high.
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Background
The management of critically ill patients in intensive care 
units (ICUs) has improved during the last decades yield-
ing increased survival of patients with complex medical 
and surgical issues. Such patients are at high risk of inva-
sive infections, including invasive candidiasis (IC) [1, 2]. 
IC can involve any organ; bloodstream infections, com-
plicated intra-abdominal infections (cIAI), and deep-
seated infection are the most frequently diagnosed [3, 4]. 
In the EUROBACT study, fungal bloodstream infections 
represented 7.8  % of monomicrobial infections [5]. The 
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mortality rate of IC remains high. In the EPIC II study, 
mortality rate of candidaemia was 42.6 % [2].
Diagnosing IC remains difficult, and requires often 
some days [3, 6, 7]; in addition, blood cultures have insuf-
ficient diagnostic accuracy [4, 8, 9]. Of note, while some 
studies showed a delayed administration of systemic 
antifungal therapy (SAT) was associated with increased 
mortality [10–12], others did not found any relationship 
between prognosis and the timing of initial therapy [13, 
14]. Therefore, SAT is often initiated empirically, despite 
the lack of consensus on decision-making criteria [3, 15]. 
Some scores based on risk factors-based predictions have 
been set to help clinicians [16–18]; however, their posi-
tive predictive value remains insufficient.
As per IDSA and ESCMID guidelines, an appropriate 
management of IC includes the administration of the 
appropriate SAT [3, 4]. For suspected invasive candidiasis 
(SIC) as for proven candidaemia, IDSA recommends to 
use fluconazole or an echinocandin, preferably echino-
candin for more severe patients, whereas ESCMID guide-
lines do not modulate their recommendations according 
to patient severity.
This prospective study intended to describe the man-
agement of IC in French ICUs, including the epidemiol-




AmarCAND2 is a multicenter, prospective, observational 
study, involving French ICUs having managed at least 
one IC within the past year. Most centers were involved 
in the previous AmarCAND study [19].
The study primarily aimed to describe the prescrib-
ing practices for SAT in ICUs. SAT could be targeted for 
patient with microbiologically proven invasive candidia-
sis (PIC), or empirically instituted for SIC. The secondary 
objectives included the analysis of the Candida species 
involved in the IC, and of the patient outcome according 
to the final IC diagnosis, and finally of prognostic fac-
tors associated with mortality of the overall population 
of patients with a definite diagnosis of IC. In addition, 
the level of compliance of the participating ICUs with 
the ESCMID guidelines (at draft stage when the study 
was conducted) and with the IDSA guidelines was ana-
lyzed. With respect to IDSA guidelines, the use of echi-
nocandin for severely ill patients, an appropriate source 
control (e.g., central venous catheter (CVC) removal in 
case of candidaemia), and de-escalation for fluconazole-
susceptible strains when the patient is stabilized were 
evaluated. Regarding ESCMID guidelines, the compli-
ance with the following recommendations was evaluated: 
a preferred use of echinocandin, the removal of any CVC 
in case of candidaemia (if not possible, echinocandin or 
liposomal amphotericin B use is recommended), and de-
escalation to be considered after 10 days of treatment for 
candidaemia.
The study was designed and overseen by an inde-
pendent Scientific Committee, and coordinated by a 
clinical research organization. Investigators enrolled 
patients according to the study protocol and managed 
them according to their own clinical judgment. The Eth-
ics Committee of the French Intensive Care Society and 
the French National Committee for Data Protection and 
Freedom of Information approved the study. According 
to French regulations, such an observational study does 
not require patients to sign an informed consent.
Patients
Investigators enrolled adult patients requiring SAT for 
PIC or SIC, during their ICU stay (≥48  h post-admis-
sion), except patients with recent (<15 days) solid organ 
transplant, or neutropenia (absolute neutrophil count 
<1  ×  1012 cells/L), or those receiving SAT prophylacti-
cally or for a mold infection.
Clinical and mycological data collection and definition
Data were collected using an electronic case report 
form. At the initiation of SAT, the patient was enrolled, 
and data were collected (Additional file  1: Clinical data 
collection).
At the time of SAT initiation, patients were divided into 
two groups. Patients for whom the presence of a posi-
tive microbiologic specimen prompted initiation of SAT 
were included in the PIC group. Patients for whom only 
a suspicion of IC led to initiate SAT were included in the 
SIC group. Nevertheless, in this later group, patients may 
ultimately have a documented IC if appropriate samples 
drawn before SAT initiation yielded Candida spp.
Documented IC was defined as candidaemia, cIAI, 
or deep-seated candidiasis. Candidaemia was defined 
by the presence of ≥1 positive blood culture for Can-
dida spp. A positive microscopic examination or cul-
ture for Candida spp. from a peritoneal sample drawn 
during surgery or percutaneously, excluding drain 
samples, defined cIAI. Finally, deep-seated candidiasis 
was defined by a positive specimen from a deep organ 
or fluid usually sterile (except urine and respiratory 
secretions).
Mycological tests
The mycology results provided by the laboratory of each 
hospital enabled patients to be classified as candidae-
mia, cIAI, deep-seated infection, or not proven infection. 
Isolates were classified as susceptible, susceptible-dose 
dependent, or resistant to antifungals, using various 
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methods and according to the manufacturers’ recom-
mendations. In France, the main marketed methods used 
in routine laboratories refer to CLSI interpretive catego-
ries (http://www.clsi.org). E-test method (BioMérieux, 
France) was used in 75 % of the centers.
Modification of initial antifungal treatment
In case of initial SAT modification, the investigator was 
asked to record the date and reason(s) for the modifica-
tion. If a new SAT was started, the antifungal agent was 
recorded.
Patient outcome
At the end of the SAT, the Candida infection outcome, 
the date of ICU discharge, and the vital status of all 
patients at that date and at day 28 were collected.
Statistical analyses
Statistical analyses were performed using SAS (version 
9.3). Variables were expressed as mean with standard 
deviation for numerical variables and as frequencies and 
percentages for categorical variables. Groups were com-
pared using Wilcoxon, Chi-square, or Fisher’s exact tests, 
as appropriate, with a statistical significance threshold of 
0.05.
A stepwise logistic regression analysis was per-
formed to identify risk factors associated with mortal-
ity on day-28, regardless of its cause. In order to identify 
independent risk factors for mortality, variables were 
included in the multivariate model if the P value was 
≤0.20 in bivariate analysis. Adjusted Odds ratios (AOR) 
were computed using logistic regression analysis includ-
ing the independent predictors of mortality.
All statistical analyses were performed using SAS soft-
ware, V9.1.
Results
From Oct. 2012 to Oct. 2013, 87 ICUs enrolled 870 
patients (Fig.  1), of whom 35 were excluded for non-
respect of inclusion criteria (n = 6) and for missing data 
(n = 29). So, we studied 835 patients, 291 with PIC when 
SAT was started and 544 for whom SAT was started for 
SIC. Among the 291 patients with PIC at SAT initiation, 
candidaemia, cIAI, and deep-seated infections were diag-
nosed in 141, 129, and 45 patients, respectively (24 had 
infections at multiple sites).
Characteristics of patients at the ICU admission are 
listed in the Additional file  1: Table E1. Characteristics 
at SAT initiation are described in Table 1. Centers which 
enrolled more than 22 patients enrolled more SIC com-
pared to PIC; otherwise centers did not differ signifi-
cantly for the rate of PIC and SIC enrolled (Additional 
file 1: Table E2).
In the SIC group, the clinical and microbiological 
features taken into account for initiating empiric SAT 
are reported in Additional file  1: Table E3. Of note, 
Fig. 1 Disposition of patients enrolled and analyzed. IC invasive candidiasis, cIAI complicated intra‑abdominal infections
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investigators reported that 70.4  % patients had a septic 
shock, 50.9  % a recent surgery, and 36.0  % a persistent 
fever. For 54.6 % of patients with empiric SAT, 4 to 8 fea-
tures were reported (and from 2 to 10 features for 75 % of 
patients); up to 14 features were reported.
The initial SAT was based on a single agent for most 
patients (Table  2; Additional file  1: Doses of antifungal 
agents). Median doses of antifungal agents are reported 
in additionnal file 1. The text in additional file was as fol-
lows: At SAT initiation, the median doses of fluconazole, 
voriconazole, caspofungin and micafungin were 800 mg, 
800 mg, 70 mg and 100 mg, respectively. On days 2 to 4, 
doses were 400 mg, 400 mg, 50 mg and 100 mg, respec-
tively. The comparison of patients according to the SAT 
type, echinocandins vs. azoles, showed that patients 
receiving an echinocandin had higher severity scores 
both on ICU admission and at the time of SAT initiation, 
and a higher rate of septic shock at SAT initiation (Addi-
tional file  1: Table E4, Factors associated with echino-
candin prescription).Addtional file 1. The following text 
could be related to this insert: A multivariate analysis was 
conducted to analyze the factors associated with echi-
nocandin prescription. Variables with a p-value of 0.2 in 
an univariate analysis were introduced in a multivariate 
Table 1 Characteristics of patients with initially proven and suspected invasive candidiasis
The results are given as n (%) or mean ± SD, when indicated
SAT systemic antifungal therapy, ICU intensive care unit, SOFA sequential organ failure assessment; SAPS II: simplified acute physiology score
a Risk factors as per IDSA and ESCMID guidelines (3, 4)
Patients’ characteristics SAT for initially proven  
invasive candidiasis
N = 291





 Age (years) 62.2 ± 15.4 61.9 ± 14.5 0.93
 Male gender 185 (63.6) 337 (62.0) 0.64
Reason for admission to ICU
 Medical 119 (40.9) 268 (49.3) 0.02
 Surgical 161 (55.3) 260 (47.8) 0.04
 Trauma 16 (5.5) 16 (2.9) 0.08
C‑reactive protein (mg/L) 165.9 ± 109.4 173.1 ± 122.6 0.67
Creatinine (µmol/L) 145.8 ± 109.6 132.1 ± 96.9 0.13
Red blood cell transfusion in ICU 163 (56.0) 289 (53.1) 0.42
Platelet transfusion in ICU 60 (20.6) 119 (21.9) 0.67
At SAT initiation
 Length of hospital stay before SAT (days) 13 [6; 23] 11 [4; 20] <0.01
 Length of ICU stay before SAT (days) 5 [2; 14] 4 [0; 11] <0.01
 Body temperature (°C) 37.6 ± 1.3 37.7 ± 1.3 0.34
 SAPS II 46.2 ± 18.0 50.1 ± 18.7 0.006
 SOFA score 7.3 ± 4.8 8.3 ± 4.3 0.0007
 Septic shock 120 (41.2) 330 (66.7) <0.0001
 Severe sepsis 118 (40.6) 203 (37.3) 0.36
Risk factors for invasive candidiasisa
 Invasive mechanical ventilation 196 (67.4) 458 (84.2) <0.0001
 Central venous catheter 278 (95.5) 526 (96.7) 0.44
 Urinary catheterization 280 (96.2) 516 (94.9) 0.50
 Antibiotic treatment 268 (92.1) 481 (88.4) 0.12
 Total parenteral nutrition 149 (51.2) 235 (43.2) 0.03
 Hemodialysis or hemodiafiltration 92 (31.6) 160 (29.4) 0.51
 Corticosteroid treatment 55 (18.9) 151 (27.8) 0.005
Surgery just before or during ICU stay 197 (67.7) 341 (62.7) 0.15
 Abdominal surgery 156 (78.2) 263 (79.2) 0.80
 Scheduled abdominal surgery 16 (10.3) 48 (18.3) 0.03
 Emergency abdominal surgery 140 (89.7) 215 (81.7) 0.03
 Mortality on D28 96 (34.4 %) 163 (31.6 %) 0.42
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logistic regression. The selected variables were the fol-
lowings: (1) at ICU admission: SAPSII, gender, BMI, 
presence of comorbidities, type of admission (medical 
reasons vs. other), surgery before ICU admission, inter-
val from hospitalization; (2) at SAT initiation: parenteral 
nutrition, presence of bacteria, septic shock, antibacte-
rial therapy, red blood cell transfusion, creatinine, cen-
tral venous catheter, proven IC (vs. suspected). The final 
model showed that a proven invasive candidiasis, septic 
shock, SAPSII score greater than 46, ICU admission for 
medical reasons, a creatinine greater than 103  µmol/L, 
and the presence of a central venous catheter increased 
significantly the probability of echinocandin prescription 
(see Table E4).
Overall, 325 isolates were identified among the 291 
patients with PIC (Table  3). Candida albicans was the 
most common pathogen. Candida spp. were associated 
with bacterial pathogens in 19/141 patients with candi-
daemia and 76/129 patients with cIAI. Among the 544 
patients with SIC, IC was ultimately proven for 112 for 
whom 128 isolates were identified (Fig. 1). Again, C. albi-
cans was the most common pathogen (Table 3). The com-
parison of patients with initially proven IC (n = 291) vs. 
patients with ultimately proven IC (n =  112) shows the 
following significant differences (Additional file 1: Table 
E5): on ICU admission, patients with initially proven IC 
had a higher SOFA score; at SAT initiation, patients with 
ultimately proven IC were more often mechanically ven-
tilated, had undergone more often surgery before or dur-
ing ICU stay, and exhibited more often septic shock.
In the overall population, IC was thus finally proven 
for 403/835 patients (Fig. 1). Among patients with deep-
seated IC (n  =  74), infections mainly involved pleura 
(n =  22), hepato-biliary-pancreatic tract (n =  14), bone 
or joints (n =  4), skin and soft tissues (n =  4), medias-
tinal space (n = 4), and heart valve or vascular prosthe-
sis (n =  3). The comparison of patients with proven IC 
(n = 403) with patients without IC (n = 432) is reported 
in Additional file 1: Table E6. At ICU admission, patients 
with IC exhibited a significant lower SAPS II. At SAT ini-
tiation, patients with IC exhibited a lower SOFA score, 
and had less often septic shock, invasive mechanical ven-
tilation, and previous corticosteroid treatment, whereas 
surgery just before or during ICU stay was more often 
present.
The median time elapsed between sample draw and 
mycological results was 1 day for the positivity to yeasts, 
3–4 days for the species identification, and 5–6 days for 
the antifungal susceptibility. Local laboratory MIC50 
(number of isolates; IQR) for the main antifungals tested 
was as follows: fluconazole, 0.25 mg/L (n = 283; 0.125–
1.50), voriconazole, 0.02  mg/L (n  =  228; 0.01–0.06), 
Table 2 Summary of initial antifungal treatment in patients with proven and suspected invasive candidiasis
The results are given as n (%)
SAT systemic antifungal therapy
Antifungal treatment SAT for proven invasive  
candidiasis
N = 291
SAT for suspected invasive 
candidiasis
N = 544
Monotherapy 287 (98.6 %) 541 (99.5 %)
 Polyenes 6 (2.1 %) 6 (1.1 %)
  Amphotericin B deoxycholate 0 3
  Liposomal amphotericin B 4 3
  Amphotericin B lipid complex 2 0
 Azoles 99 (34.5 %) 248 (45.8 %)
  Fluconazole 99 244
  Voriconazole 0 4
 Echinocandin 182 (63.4 %) 287 (53.0 %)
  Caspofungin 160 252
  Micafungin 20 34
  Anidulafungin 0 1
 Flucytosine 0 0
Combination therapy 4 3
 Liposomal amphotericin B and flucytosine 0 2
 Caspofungin and fluconazole 2 0
 Caspofungin and voriconazole 1 0
 Caspofungin and flucytosine 1 0
 Amphotericin B deoxycholate and micafungin 0 1
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caspofungin, 0.09  mg/L (n  =  253; 0.05–0.125), and 
micafungin, 0.02  mg/L (n =  74; 0.01–0.03). The overall 
rate resistance among all isolates was 13 % for fluconazole 
(including 20.3 % among C. glabrata), 2 % for voricona-
zole, 1.25 % for micafungin, and 0.7 % for caspofungin.
The initial SAT was modified for 142 (48.8 %) patients 
with PIC, 4.77 ± 4.01 days after initiation. The changes 
were motivated by mycological documentation in 118 
patients. They were largely for selecting another anti-
fungal drug (139/142). Main modifications were de-
escalation from an echinocandin to fluconazole for 93 
patients, and escalation from fluconazole to an echi-
nocandin for 20 patients. The initial SAT was termi-
nated or modified for 180 (33.1  %) patients with SIC, 
5.37  ±  5.25  days after initiation. SAT was terminated 
in 76 patients (confirmation of the bacterial origin of 
the infection) and was modified in 104, mainly accord-
ing to mycological documentation. De-escalation from 
an echinocandin to fluconazole was performed in 60 
patients, and escalation from fluconazole to an echino-
candin occurred in 30.
With regard to source control, a surgical procedure 
(n =  191) or a percutaneous drainage of intra-abdomi-
nal abscess (n =  2) was performed in all patients with 
cIAI. CVC was removed in 87 (54.3  %) patients with 
candidaemia. This removal occurred 2  days or later 
after blood sampling identifying candidaemia in 34.4 % 
of cases. Among the 73 patients without CVC removal, 
6 died before the result of blood sampling identifying 
Candida spp. was known, and 5 had no CVC. Among 
the 62 remaining patients, 43 patients received an 
echinocandin.
Compliance to three main recommendations of IDSA 
guidelines was analyzed; (1) echinocandin was used for 
182 (62.5  %) of patients with PIC, and 287 (52.7  %) of 
patients with SIC; (2) CVC was removed in 87 (54.3 %) 
patients with candidaemia; (3) de-escalation was under-
taken 5 days after SAT initiation for 142 (17 %) patients. 
At least one recommendation was applied for 506 
patients. With regard to the compliance to the similar 
recommendations of ESCMID guidelines, (1) echinocan-
din was used for 182 (62.5 %) of patients with PIC, and 
287 (52.7 %) of patients with SIC; (2) CVC was removed 
in 87 (54.3 %) patients with candidaemia. Among the 62 
patients with CVC and mycological results known while 
still alive, 43 (69.3 %) were treated with echinocandin; (3) 
10 days after SAT initiation, among the 484 patients still 
alive in ICU, de-escalation was undertaken for 13 (2.7 %) 
patients. At least one recommendation was applied for 
505 (60.5 %) patients.
The clinical outcome of the patients according to their 
final diagnosis and SAT duration is depicted in Table 4. 
Cure rates ranged from 55 to 70  %. The mortality rates 
were 40.0 % in candidaemia, 25.4 % in cIAI, and 26.7 % 
in deep-seated candidiasis. In patients with vs. without 
immunodeficiency, mortality rates were 58.3 vs. 37.3  % 
Table 3 Results of mycological cultures of samples from the AmarCAND2 patients, according to their status at SAT initia-
tion: invasive candidiasis either proven, or suspected
The results are given as n (%)
SAT systemic antifungal therapy, IC invasive candidiasis
SAT for proven  
invasive candidiasis
N = 291





Patients with at least an isolate  
identified, i.e., proven IC
291 (100) 112 (20.6) 403 (48.3 %)
Number of identified isolates 325 128 453
C. albicans 206 (63.4) 90 (70.3) 296 (65.3)
C. glabrata 54 (16.6) 18 (14.0) 72 (15.9)
C. parapsilosis 19 (5.8) 2 (1.6) 21 (4.6)
C. tropicalis 14 (4.3) 6 (4.7) 20 (4.4)
C. krusei 10 3 13
C. lusitaniae 9 1 10
C. kefyr 6 2 8
C. guilliermondii 3 1 4
C. dubliniensis 2 0 2
C. norvengiensis 1 1 2
C. pulcherina 1 0 1
Other 0 4 4
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(p  =  0.11), 40 vs. 23.65  % (p  =  0.11), and 30 vs. 25  % 
(p =  0.71), respectively. Among patients with candidae-
mia, the mortality rate was 38 % in patients with isolated 
candidaemia (n =  54/141), 45 % in patients with candi-
daemia associated with cIAI (n  =  5/11), and 62.5  % in 
patients with candidaemia associated with deep-seated 
candidiasis (n  =  5/8) (p  =  0.4). Among patients with 
candidaemia and non-immunosuppressed (n  =  134), 
the mortality rate was 37.3 % (50/134). It was not signifi-
cantly different according to the removal of the CVC (35 
vs. 40 %; p = 0.59), to the early SAT initiation, i.e., before 
the knowledge of positive blood culture (31 vs. 38  %; 
p =  0.61), or to the use of echinocandin as SAT (39 vs. 
31 %; p = 0.42).
In the overall population of patients with proven IC 
(n  =  403), 121 patients died. Factors associated with 
28-day mortality are reported in Table 5. In multivariate 
analysis, four independent prognostic factors were iden-
tified: immunosuppression (Odds Ratio (OR)  =  1.977: 
1.03–3.794 95 % confidence interval (CI), p = 0.04), age 
(OR = 1.035; 1.017–1.053 95 % CI; p < 0.001), SAPS >46 
on ICU admission (OR  =  2.894; 1.81–4.626 95  % CI; 
p  <  0.001), and surgery just before or during ICU stay 
(OR = 0.473; 0.29–0.77 95 % CI; p < 0.001). Of note, early 
SAT instituted before the knowledge of positive sample 
did not influence outcome (OR  =  1.507: 0.891–2.548 
95 % CI; p = 0.13).
Discussion
This study on SAT in French ICUs enrolled 291 patients 
with PIC and 544 with SIC. Patients receiving SAT for 
SIC were more severely ill than those having SAT for PIC: 
they had higher severity scores and more often septic 
shock. They had more often known IC risk factors. Initial 
SAT was mainly based on echinocandins. However, in 
case of adaptation, fluconazole was mainly chosen. Mor-
tality remains high, particularly for candidaemia (40.0 %).
The appropriate IC management includes the admin-
istration of the right antifungal agent [3, 4]. Regarding 
comparable population set within the previous Amar-
CAND study, caspofungin was administered to 18.1  % 
of patients, while 72.7  % received fluconazole [19]. In 
contrast, at SAT initiation for AmarCAND2, caspo-
fungin was the most frequent agent administered. It 
was significantly preferred for more severe patients, for 
targeted as for empiric SAT. ESCMID guidelines rec-
ommend treating patients with suspected IC with echi-
nocandin [3], similarly to IDSA guidelines [4], although 
the latter recommends using echinocandin for severely 
ill patients. Our study patients were admitted in ICU, 
thus severely ill, which is consistent with the rather high 
rate of patients treated with echinocandin (63.4 % of PIC 
patients, 53.0  % of SIC patients). Indeed, echinocandin 
were significantly more often administered in case of ill-
ness severity such as septic shock or high severity scores. 
Table 4 Clinical evolution as a function of the final diagnosis of invasive candidiasis










SOFA score at D0
 Mean ± SD 7.7 ± 4.8 7.2 ± 4.5 7.7 ± 4.5 8.4 ± 4.3
 Median (min; max) 7 (0; 23) 7 (0; 19) 7.5 (0; 17) 8 (0; 24)
SOFA score at D7
 Mean ± SD 6.9 ± 6.0 4.9 ± 5.1 6.5 ± 5.8 6.8 ± 5.3
 Median (min; max) 5 (0; 24) 3 (0; 24) 5 (0; 21) 6 (0; 24)
Clinical outcome n (%)
 Cured 89 (55.6) 135 (70.0) 48 (64.9) 261 (60.4)
 Failure 27 (16.85) 20 (10.35) 12 (16.2) 42 (9.7)
 Not determined 33 (20.6) 27 (14.0) 13 (17.6) 89 (20.6)
 Information not available 11 (6.9) 11 (5.7) 1 (1.3) 40 (9.3)
Status on D28, n (%)
 Alive 90 (56.3) 135 (70.0) 53 (71.6) 271 (62.7)
 Dead 64 (40.0) 49 (25.4) 19 (26.7) 138 (32.0)
Lost to follow‑up after ICU discharge 6 (3.7) 9 (4.6) 2 (2.7) 23 (5.3)
Length of SAT among those alive (days)
 Mean ± SD 24 ± 16 20 ± 14 28 ± 25 12 ± 10
 Median 20 17 21 10
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Another recommendation of both guidelines which was 
evaluated relates to a careful control of source. Most, but 
not all, patients with candidaemia had CVC, which was 
removed in one patient out of two. This rate is not very 
high; however, IDSA and ESCMID recommendations dif-
fer slightly. IDSA guidelines recommend CVC removal, 
whereas ESCMID guidelines add that patients whom 
CVC cannot be removed should be treated with echi-
nocandin or liposomal amphotericin B. Indeed, among 
patients with candidaemia and CVC not removed, most 
patients (69.3  %) received echinocandin. For patients 
with cIAI, the source control is abdominal surgery or at 
least peritoneal drainage, which was undertaken for all, 
as it was a study inclusion criterion. The last recommen-
dation of both guidelines which was evaluated relates to 
the de-escalation of SAT. According to IDSA guidelines, 
de-escalation should be performed in case of IC due to 
fluconazole-susceptible strains when the patient becomes 
stable, whereas ESCMID guidelines recommend de-esca-
lation after ten days of intravenous SAT for patients with 
candidaemia. Overall, regarding de-escalation, IDSA rec-
ommendation was applied for 17  % of all patients. The 
compliance rate with IDSA or ESCMID guidelines is 
rather poor. However, although ESCMID guidelines were 
circulated through 2011 ECCMID workshop slides, they 
were officially issued after the study start. Regarding the 
Table 5 Factors associated with 28-day mortality in patients with proven IC
The results are given as n(%) or median (min; max), when indicated
SAT systemic antifungal therapy, ICU intensive care unit, SOFA sequential organ failure assessment, SAPS II simplified acute physiology score
Patients’ characteristics Survivors (N = 273) Non survivors (N = 130) P value
At ICU admission
 Age 61.5 [51; 70.1] 66.5 [57.9; 78.8] <.01
 Male gender 171 (62.6) 83 (63.8) 0.81
 SAPSII 42 [30; 52] 56 [45; 67] <0.01
 SOFA score 8 [5; 10] 9.5 [7; 13] <0.01
 Immunosuppression 29 (10.6) 31 (23.8) <0.01
Reason for admission to ICU <0.01
 Medical 88 (32.2) 66 (50.8)
 Elective surgical 24 (8.8) 14 (10.8)
 Emergency surgical 144 (52.7) 48 (36.9)
 Trauma 17 (6.2) 2 (1.5)
Red blood cell transfusion in ICU 141 (51.6) 79 (60.8) 0.09
Platelet transfusion in ICU 49 (17.9) 36 (27.7) 0.03
 At SAT initiation
Body temperature (°C) 38 [37; 38.5] 37.6 [36.9; 38.2] <0.01
SOFA score 6 [3; 9] 9 [6; 13] <0.01
Septic shock 110 (40.3) 72 (55.4) <0.01
Severe sepsis 117 (42.9) 48 (36.9) 0.26
Invasive mechanical ventilation 191 (70) 97 (74.6) 0.33
Central venous catheter 261 (95.6) 126 (96.9) 0.53
Urinary catheterization 259 (94.9) 129 (99.2) 0.03
Hemodialysis or hemodiafiltration 68 (24.9) 53 (40.8) <0.01
Total parenteral nutrition 135 (49.5) 64 (49.2) 0.97
Corticosteroid treatment 44 (16.1) 38 (29.2) <0.01
Surgery just before or during ICU stay 209 (76.6) 75 (57.7) <0.01
Initial SAT 0.26
 Amphotericin B 4 (1.5) 2 (1.5)
 Fluconazole 112 (41) 40 (30.8)
 Voriconazole 2 (0.7) 1 (0.8)
 Echinocandins 155 (56.8) 87 (66.9)
SAT instituted before the knowledge of positive sample 0.14
 No 191 (70) 100 (76.9)
 Yes 82 (30) 30 (23.1)
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duration of SAT, it was shorter among patients whose 
IC was eventually not documented than among patients 
with proven IC, and similar to that observed in the Fon-
giDay study: 11.7  days on average and no longer than 
16 days [20].
In our study, C. albicans remained the leading Candida 
species, followed by C.  glabrata, which is the leading 
non-albicans pathogen in France [19, 21], in Northern 
European countries [22–24], and in the US [11, 25]. This 
rather low rate of C. glabrata, close to 16 % in our study, 
explains why fluconazole is chosen in half of patients. 
This rate is comparable to that observed during the pre-
vious AmarCAND study [19]. It remained stable despite 
the use of echinocandins, in contrast with the results of a 
recent French study showing a higher rate of C. glabrata 
(20.0  %), increasing after previous exposure to caspo-
fungin [26]. Regarding antifungal susceptibility, antifun-
gal resistance was uncommon except for 13 % of isolates 
classified as fluconazole-resistant.
Mycological cultures require some days for the full 
process from the sampling to the susceptibility results. 
Mycological results were the main drivers for treatment 
modifications, which occurred in almost half of the tar-
geted SATs. Empiric SAT was modified in one-third of 
patient, more often based on mycological results than on 
clinical changes. In 42  % patients whom treatment was 
modified, the SAT was terminated based on positive bac-
teriological results combined with negative mycological 
tests results. For empiric as for targeted SAT, the most 
frequent initial drug was caspofungin, and the most fre-
quent agent modification was de-escalation to flucona-
zole. The delayed availability of mycological results likely 
explains the high rate of patients with empiric SAT [27]. 
Other laboratory tests, not based on cultures, have been 
developed, such as Candida-specific polymerase-chain-
reaction, or tests based on the detection of yeasts anti-
gens, or of antibodies directed against these antigens. In 
our study, the use of non-culture-based diagnostic meth-
ods to suspect IC and so to begin SAT was still anecdo-
tal (less than 4 %). These tests are now recommended by 
the ESCMID guidelines for the IC diagnosis [8], and will 
probably be increasingly implemented as far as robust 
and standardized methods will be available.
The identification of high-risk patients who may ben-
efit from empiric SAT is still challenging. Major risk fac-
tors for IC are well known [3, 4, 7, 28]; however, they are 
so common in ICU patients than other tools are needed. 
The Candida colonization index and the Candida score 
are useful for their good negative predictive value ena-
bling to identify patients at low risk of IC [16, 18]. 
Whether the study investigators used these scores was 
not captured. Nevertheless, it could be suggested that, 
in this study, the overall conditions leading investigators 
to initiate empiric SAT had both low specificity since a 
minority of patients with empiric SAT had a secondar-
ily proven IC (112/544) and low sensitivity since only a 
minority of patients with proven IC benefited from an 
early SAT (19/141 candidaemia, 64/129 cIAI, and 29/45 
deep-seated infections). These rates are disappointing 
compared to results showed by Bruyere et al. in a study 
on ICU patients with suspected IC based on uncon-
trolled sepsis despite at least one 2-day course of antibac-
terial agents: the use of the Candida score with a cut-off 
point at 3 or more triggering SAT prescription for these 
patients was associated with sensitivity, specificity, posi-
tive and negative value of 69.2, 82.1, 69.2, and 82.1  %, 
respectively [29]. However, the rate of secondarily proven 
IC among those empirically treated (20.4 %) likely reflects 
the specific interest of participating ICUs regarding inva-
sive candidiasis risk assessment.
IC remains associated with a high mortality rate. In our 
study, we observed a day-28 mortality rate set at 40, 25.7, 
and 25.4  % for candidaemia, deep-seated IC, and cIAI, 
respectively. Such a result is in accordance with literature 
data. In a nationwide US study collecting data on blood-
stream infections from 1995 to 2002, the crude mortal-
ity rate of candidaemia among ICU patients reached 
47  % [30]. In AmarCAND1 study, the 30-day mortality 
was 45.9  % in patients with PIC [19]. Finally, in a study 
conducted from 2002 to 2010 among ICU patients with 
candidaemia, the day-28 mortality rate increased from 
41.5 to 56.9 % [26]. Among risk factors of poor prognosis 
identified in this study, a greater age, immunodeficiency, 
and SAPSII >46 are well-known risk factors of poor prog-
nosis in ICU patients overall. A recent surgery was not 
previously identified as a protective factor for IC prog-
nosis. However, the surgical origin of ICU patients was 
already identified as a factor of good prognosis for candi-
daemia [31].
This study had some limitations. First, it was conducted 
in one country and results could not fully be applied to 
other countries. However, it involved a large number of 
ICUs with a broad case-mix range of medical and surgi-
cal patients, and provides an accurate picture of the SAT 
practices. Second, it was an observational study, without 
any study-specific intervention; however, it is the first 
study comparing the management of PIC and SIC within 
the same establishments. Third, microbiological methods 
used to determine MIC were different in the participant 
hospitals, leading to interpret these results with caution. 
Finally, fungal infection management was likely a field 
of interest for most investigators; therefore, physicians 
were more likely to know and follow the guidelines and 
to administrate properly the SAT. In addition, we cannot 
ensure that absolutely all consecutive patients receiv-
ing SAT were included in the study. Therefore, it might 
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hamper the extrapolation of these study results to other 
ICUs.
Conclusion
This large prospective observational study conducted 
showed the management of IC and the strategy of SAT 
use in French ICUs. Almost half of patients had an ulti-
mately proven IC, of whom only 27 % received early SAT 
before mycological documentation. This later point could 
explain why the mortality associated to IC remained 
high, particularly in patients with candidaemia. ESC-
MID guidelines were not officially issued at the time our 
study was conducted, and there are some discrepancies 
between the IDSA and the ESCMID recommendations 
we evaluated, which altogether might have contributed 
to the rather low rate of compliance observed in this 
study. Comparatively to AmarCAND1, the diversity of 
the Candida species was maintained, the rate of IC due 
to C. albicans remained high, and the rate of C. glabrata 
remained stable. Further analyses will be conducted to 
further describe epidemiological and mycological study 
results.
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